These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 25939291)

  • 1. Familial hypercholesterolemia.
    Bouhairie VE; Goldberg AC
    Cardiol Clin; 2015 May; 33(2):169-79. PubMed ID: 25939291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial Hypercholesterolemia.
    Bouhairie VE; Goldberg AC
    Endocrinol Metab Clin North Am; 2016 Mar; 45(1):1-16. PubMed ID: 26892994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Severe familial hypercholesterolemia treatment].
    Vrablík M; Freiberger T; Bláha V; Češka R
    Vnitr Lek; 2016; 62(11):895-901. PubMed ID: 28128576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modern Management of Familial Hypercholesterolemia.
    Duell PB; Jialal I
    Metab Syndr Relat Disord; 2016 Dec; 14(10):463-467. PubMed ID: 27797643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia.
    Ito MK; Watts GF
    Drugs; 2015 Oct; 75(15):1715-24. PubMed ID: 26370207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy.
    Yamamoto A; Harada-Shiba M; Endo M; Kusakabe N; Tanioka T; Kato H; Shoji T
    Atherosclerosis; 2006 May; 186(1):126-31. PubMed ID: 16043185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab.
    Tanaka A; Inaguma D; Watanabe Y; Ito E; Kamegai N; Shimogushi H; Shinjo H; Koike K; Otsuka Y; Takeda A
    Intern Med; 2017; 56(12):1531-1535. PubMed ID: 28626179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.
    Stefanutti C; Blom DJ; Averna MR; Meagher EA; Theron Hd; Marais AD; Hegele RA; Sirtori CR; Shah PK; Gaudet D; Vigna GB; Sachais BS; Di Giacomo S; du Plessis AM; Bloedon LT; Balser J; Rader DJ; Cuchel M;
    Atherosclerosis; 2015 Jun; 240(2):408-14. PubMed ID: 25897792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
    Robinson JG
    J Manag Care Pharm; 2013 Mar; 19(2):139-49. PubMed ID: 23461430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein apheresis.
    Moriarty PM; Hemphill L
    Cardiol Clin; 2015 May; 33(2):197-208. PubMed ID: 25939293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.
    Leipold R; Raal F; Ishak J; Hovingh K; Phillips H
    Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
    Vishwanath R; Hemphill LC
    J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?
    Santos RD
    Atheroscler Suppl; 2014 Sep; 15(2):19-25. PubMed ID: 25257073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children.
    Page MM; Bell DA; Hooper AJ; Watts GF; Burnett JR
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):387-403. PubMed ID: 24840266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances.
    Stefanutti C; Thompson GR
    Curr Atheroscler Rep; 2015 Jan; 17(1):465. PubMed ID: 25410046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins.
    Geiss HC; Otto C; Parhofer KG
    Metabolism; 2006 May; 55(5):599-604. PubMed ID: 16631435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial Hypercholesterolemia: Global Burden and Approaches.
    Tokgozoglu L; Kayikcioglu M
    Curr Cardiol Rep; 2021 Sep; 23(10):151. PubMed ID: 34480646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of homozygous familial hypercholesterolemia in real-world clinical practice: A report of 7 Italian patients treated in Rome with lomitapide and lipoprotein apheresis.
    Stefanutti C; Morozzi C; Di Giacomo S; Sovrano B; Mesce D; Grossi A
    J Clin Lipidol; 2016; 10(4):782-789. PubMed ID: 27578108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease.
    Vogt A; Parhofer KG
    Expert Opin Pharmacother; 2013 Apr; 14(6):691-7. PubMed ID: 23477485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Familial hypercholesterolemia: current treatment options and patient selection for low-density lipoprotein apheresis.
    Hemphill LC
    J Clin Lipidol; 2010; 4(5):346-9. PubMed ID: 21122676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.